NCT05091528
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with untreated brain metastases
https://ClinicalTrials.gov/show/NCT05091528